JP Morgan Chase
BXRX

JP Morgan Chase’s Baudax Bio, Inc. Common Stock BXRX Stock Holding History

JP Morgan Chase’s Portfolio BXRX Stock Details BXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-1,511
Closed -$3K – 7583
2023
Q1 		$3K Buy
+1,511
New +$3.84K ﹤0.01% 6381
2022
Q4 		– Hold
0
– – – 7395
2022
Q3 		– Hold
0
– – – 7188
2022
Q2 		– Sell
-4
Closed -$187 – 7239
2022
Q1 		$0 Buy
+4
New +$738 ﹤0.01% 7304
2021
Q4 		– Hold
0
– – – 7220
2021
Q3 		– Hold
0
– – – 7019
2021
Q2 		– Hold
0
– – – 6773
2021
Q1 		– Hold
0
– – – 6007
2020
Q4 		– Hold
0
– – – 5583
2020
Q3 		– Hold
0
– – – 5935
2020
Q2 		– Sell
-2
Closed -$9.6K – 5845
2020
Q1 		$6K Hold
2
– – ﹤0.01% 5110
2019
Q4 		$19K Buy
+2
New +$17.1K ﹤0.01% 5324

Other funds holding BXRX

Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

JP Morgan Chase's BXRX Position: Q2 2023 in Review

JP Morgan Chase sold out of Baudax Bio, Inc. Common Stock (BXRX) in Q2 2023, closing a stake of 1,511 shares — an estimated $3K sold.

JP Morgan Chase first reported a position in BXRX in Q4 2019 and held it in 4 quarters. The position peaked at $19K in Q4 2019. 12 funds tracked by Wall St. Rank hold BXRX as of Q2 2023.

  • JP Morgan Chase reported no remaining Baudax Bio, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • JP Morgan Chase sold 1,511 Baudax Bio, Inc. Common Stock shares in Q2 2023, an estimated $3K.
  • JP Morgan Chase first reported a position in Baudax Bio, Inc. Common Stock in Q4 2019 and held it in 4 quarters.
  • JP Morgan Chase's Baudax Bio, Inc. Common Stock position peaked at $19K in Q4 2019.
  • 12 funds tracked by Wall St. Rank held Baudax Bio, Inc. Common Stock as of Q2 2023.

Based on JP Morgan Chase's 13F filing for Q2 2023, filed 11 Aug 2023.